2017
DOI: 10.1186/s12917-017-1108-2
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of the effects of 7.2% hypertonic saline and 20% mannitol on whole blood coagulation and platelet function in dogs with suspected intracranial hypertension - a pilot study

Abstract: BackgroundHyperosmolar therapy with either mannitol or hypertonic saline (HTS) is commonly used in the treatment of intracranial hypertension (ICH). In vitro data indicate that both mannitol and HTS affect coagulation and platelet function in dogs. The aim of this study was to compare the effects of 20% mannitol and 7.2% HTS on whole blood coagulation using rotational thromboelastometry (ROTEM®) and platelet function using a platelet function analyzer (PFA®) in dogs with suspected ICH. Thirty client-owned dogs… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
24
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 16 publications
(26 citation statements)
references
References 39 publications
2
24
0
Order By: Relevance
“…39,40 However, recent clinical studies in dogs do not report a hypocoagulable effect on ROTEM parameters after a single bolus of 7.2% hypertonic saline. 41 Fluid administration may further lead to dilutional coagulopathy. 42,43 When excluding all cats with fluid treatment prior to blood sampling, the incidence of ATC would be only slightly lower with 14% and would not change the occurrence of hypercoagulability after 24 hours.…”
Section: Discussionmentioning
confidence: 99%
“…39,40 However, recent clinical studies in dogs do not report a hypocoagulable effect on ROTEM parameters after a single bolus of 7.2% hypertonic saline. 41 Fluid administration may further lead to dilutional coagulopathy. 42,43 When excluding all cats with fluid treatment prior to blood sampling, the incidence of ATC would be only slightly lower with 14% and would not change the occurrence of hypercoagulability after 24 hours.…”
Section: Discussionmentioning
confidence: 99%
“…, Yozova et al . ). In summary, there are still insufficient data to conclude whether various intravenous fluids will cause clinically significant abnormalities in platelet function.…”
Section: Abnormalities Of Platelet Function Resulting In Haemorrhagementioning
confidence: 97%
“…In a feline study, HES reduced coagulation to a greater degree than a balanced crystalloid solution alone, but platelet function was not assessed specifically (Albrecht et al 2016). Mannitol has also been shown to impair platelet aggregation but not at clinically relevant dilutions (Adamik et al 2015, Yozova et al 2017. In summary, there are still insufficient data to conclude whether various intravenous fluids will cause clinically significant abnormalities in platelet function.…”
Section: Monoclonal Gammopathymentioning
confidence: 99%
“…HTS is also a first-line treatment option for reduction of intracranial pressure in the management of traumatic brain injuries (TBI), inflammatory CNS disease or intracranial neoplasia (Mangat et al 2015, Carney et al 2017. The other common treatment option in these cases is mannitol (Yozova et al 2017a), stocked by 43.0% of practices. It remains unclear which of these two are superior in the treatment of TBI (Boone et al 2015), however, it would make sense that in patients with both TBI and hypovolaemia, HTS may be more appropriate when hypernatraemia is not an immediate concern.…”
Section: Resultsmentioning
confidence: 99%